Valeant Pharmaceuticals
Report: Allergan solicits Salix in bid to stymie hostile Valeant takeover
Medtronic CEO Ishrak seeks to reassure employees on MDT-COV deal | The week in medtech M&A
Allergan CFO Edwards steps down amid hostile Valeant takeover bid | Personnel Moves
Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO
Allergan calls out Valeant on latest earnings report : The week in medtech M&A
Feds take a closer look at Valeant’s hostile bid for Allergan
Federal authorities are taking a closer look at Allergan’s (NYSE:AGN) ongoing battle to keep unrequited acquirer Valeant Pharmaceuticals at bay.
Hologic CEO gives glowing review to major stakeholder and activist investor Carl Icahn | Medtech Wall Street news for the week of August 4, 2014
Report: Valeant’s hostile takeover hopes fade as Allergan war continues
Abbott CEO chides critics of corporate inversions | Medtech Wall Street news for the week of July 21, 2014
Allergan cuts 1,500 jobs, faces SEC complaint
Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan’s earnings.